Last reviewed · How we verify

Alyftrek — Competitive Intelligence Brief

Alyftrek (VANZACAFTOR) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]. Area: Respiratory.

marketed Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Alyftrek (VANZACAFTOR) — Vertex Pharms Inc. Alyftrek potentiates the CFTR protein to facilitate chloride ion flow into cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Alyftrek TARGET VANZACAFTOR Vertex Pharms Inc marketed Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] 2026-01-01
Kalydeco IVACAFTOR Vertex Pharms Inc marketed Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] Cystic fibrosis transmembrane conductance regulator 2012-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC] class)

  1. Vertex Pharms Inc · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Alyftrek — Competitive Intelligence Brief. https://druglandscape.com/ci/vanzacaftor. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: